Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution

Kidney International

Volumn 69, Issue 9, 2006, Pages 1507-1510

  Hoffer, L J ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Cardiovascular disease; Clinical trial; End stage renal disease; Malnutrition; Randomized controlled trials; Vitamin B

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

CLINICAL STUDY; CLINICAL TRIAL; CONFOUNDING VARIABLE; DRUG MEGADOSE; EPIDEMIOLOGY; HOMOCYSTEINEMIA IN KIDNEY AND END STATE RENAL DISEASE STUDY; HUMAN; HYPERHOMOCYSTEINEMIA; HYPOTHESIS; KIDNEY FAILURE; NEUROTOXICITY; PARENTERAL NUTRITION; PRIORITY JOURNAL; REVERSE EPIDEMIOLOGY; SHORT SURVEY; VITAMIN SUPPLEMENTATION;

CLINICAL TRIALS; FOLIC ACID; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; VITAMIN B 12;

EID: 33646494653     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000279     Document Type: Short Survey

References (63)

1. Nygard O, Vollset SE, Refsum H et al. Total homocysteine and cardiovascular disease. J Intern Med 1999; 246: 425-454.
2. Bostom AG, Selhub J. Homocysteine and arteriosclerosis: subclinical and clinical disease associations. Circulation 1999; 99: 2361-2363.
3. Mudd SH, Levy HL, Kraus JP. Disorders of transsulfuration. In: Scriver CR, Beaudet A, Sly WS, Valle D (eds). The Metabolic & Molecular Bases of Inherited Disease, 8 edn., McGraw-Hill: New York, 2001, pp 2007-2056.
4. Yap S. Classical homocystinuria: vascular risk and its prevention. J Inher Metab Dis 2003; 26: 259-265.
5. McCully KS, Wilson RB. Homocysteine theory of arteriosclerosis. Atherosclerosis 1975; 22: 215-227.
6. Mohammed R, Lamand M. Cardiovascular lesions in cobalt-vitamin B12 deficient sheep. Ann Rech Vet 1986; 17: 447-450.
7. Hofmann MA, Lalla E, Lu Y et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-683.
8. Symons JD, Mullick AE, Ensunsa JL et al. Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function. Arterioscler Thromb Vasc Biol 2002; 22: 772-780.
9. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 1997; 11: 1157-1168.
10. Zhang X, Li H, Jin H et al. Effects of homocysteine on endothelial nitric oxide production. Am J Physiol 2000; 279: F671-F678.
11. Perna AF, Acanfora F, Satta E et al. Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action. Semin Nephrol 2004; 24: 426-430.
12. Wilson KM, Lentz SR. Mechanisms of the atherogenic effects of elevated homocysteine in experimental models. Semin Vasc Med 2005; 5: 163-171.
13. McCully KS. Homocysteine and vascular disease. Nat Med 1996; 2: 386-389.
14. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association. Circulation 1999; 99: 178-182.
15. Eikelboom JW, Lonn E, Genest Jr J et al. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-375.
16. Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation 2001; 103: 163-182.
17. Refsum H, Ueland PM. Recent data are not in conflict with homocysteine as a cardiovascular risk factor. Curr Opin Lipidol 1998; 9: 533-539.
18. Ueland PM, Refsum H, Beresford SA, Vollset SE. The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 2000; 72: 324-332.
19. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. Thromb Haemostasis 1999; 81: 165-176.
20. Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials. Am Heart J 2004; 148: 34-40.
21. Schnyder G, Roffi M, Pin R et al. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl J Med 2001; 345: 1593-1600.
22. Schnyder G, Roffi M, Flammer Y et al. Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention. JAMA 2002; 288: 973-979.
23. Schnyder G, Roffi M, Flammer Y et al. Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 2003; 91: 1265-1269.
24. Lange H, Suryapranata H, De L et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350: 2673-2681.
25. Toole JF, Malinow MR, Chambless LE et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004; 291: 565-575.
26. Pfeiffer CM, Caudill SP, Gunter EW et al. Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000. Am J Clin Nutr 2005; 82: 442-450.
27. Bostom AG, Selhub J, Jacques PF, Rosenberg IH. Power shortage: clinical trials testing the 'homocysteine hypothesis' against a background of folic acid-fortified cereal grain flour. Ann Intern Med 2001; 135: 133-137.
28. Bostom AG, Jacques PF, Liaugaudas G et al. Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour. Arterioscler Thromb Vasc Biol 2001; 22: 488-491.
29. Till U, Rohl P, Jentsch A et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12. Atherosclerosis 2005; 181: 131-135.
30. Austen SK, Coombes JS, Fassett RG. Homocysteine and cardiovascular disease in renal disease. Nephrology 2003; 8: 285-295.
31. Hebert LA, Wilmer WA, Falkenhain ME et al. Renoprotection: one or many therapies? Kidney Int 2001; 59: 1211-1226.
32. Sunder-Plassmann G, Fodinger M, Buchmayer H et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol 2000; 11: 1106-1116.
33. Homocysteine Lowering TC. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J Clin Nutr 2005; 82: 806-812.
34. 6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD. J Nephrol 2003; 16: 522-534.
35. Wrone EM, Hornberger JM, Zehnder JL et al. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 2004; 15: 420-426.
36. Doshi SN, Moat SJ, McDowell IF et al. Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us? Atherosclerosis 2002; 165: 1-3.
37. Wang X, Dakshinamurti K, Musat S, Dhalla NS. Pyridoxal 5′-phosphate is an ATP-receptor antagonist in freshly isolated rat cardiomyocytes. J Mol Cell Cardiol 1999; 31: 1063-1072.
38. Kandzari DE, Dery JP, Armstrong PW et al. MC-1 (pyridoxal 5′-phosphate): novel therapeutic applications to reduce ischaemic injury. Expert Opin Investig Drugs 2005; 14: 1435-1442.
39. 6 and its requirement in chronic renal failure. Kidney Int 1997; 62: S56-S59.
40. Kasama R, Koch T, Canals-Navas C, Pitone JM. Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature. Am J Kidney Dis 1996; 27: 680-686.
41. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
42. Suliman ME, Stenvinkel P, Qureshi AR et al. Hyperhomocysteinemia in relation to plasma free amino acids, biomarkers of inflammation and mortality in patients with chronic kidney disease starting dialysis therapy. Am J Kidney Dis 2004; 44: 455-465.
43. Suliman ME, Barany P, Kalantar-Zadeh K et al. Homocysteine in uraemia - a puzzling and conflicting story. Nephrol Dial Transplant 2005; 20: 16-21.
44. Spence JD, Bang H, Chambless LE, Stampfer MJ. Vitamin intervention for stroke prevention trial: an efficacy analysis. Stroke 2005; 36: 2404-2409.
45. Hoffer LJ, Bank I, Hongsprabhas P et al. A tale of two homocysteines -and two hemodialysis units. Metabolism 2000; 49: 215-219.
46. 12. Metabolism 2002; 51: 399-402.
47. Elian KM, Hoffer LJ. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism 2002; 51: 881-886.
48. Koyama K, Usami T, Takeuchi O et al. Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation. Nephrol Dial Transplant 2002; 17: 916-922.
49. Hoffer LJ, Saboohi F, Golden M, Barre PE. Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease. Metabolism 2005; 54: 835-840.
50. Hoffer LJ, Djahangirian O, Bourgouin PE et al. Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease. Metabolism 2005; 54: 1362-1367.
51. Sombolos K, Fragia T, Natse T et al. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on homocysteine in hemodialysis patients. J Nephrol 2002; 15: 671-675.
52. 12 on homocysteine plasma concentration in hemodialysis patients. Clin Nephrol 2004; 61: 161-162.
53. Obeid R, Kuhlmann MK, Kohler H, Herrmann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 2005; 51: 196-201.
54. Bostom AG, Shemin D, Lapane KL et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 49: 147-152.
55. Moustapha A, Gupta A, Robinson K et al. Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis. Kidney Int 1999; 55: 1470-1475.
56. Bostom AG, Shemin D, Bagley P et al. Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients. Circulation 2000; 101: 2829-2832.
57. 12 and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia. Kidney Int 2001; 59: 1103-1109.
58. van Tellingen A, Grooteman MC, Bartels PM et al. Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients. Kidney Int 2001; 59: 342-347.
59. Friedman AN, Bostom AG, Selhub J et al. The kidney and homocysteine metabolism. J Am Soc Nephrol 2001; 12: 2181-2189.
60. van Guldener C, Stehouwer CD. Homocysteine and methionine metabolism in renal failure. Semin Vasc Med 2005; 5: 201-208.
61. Suliman ME, Anderstam B, Lindholm B, Bergstrom J. Total, free, and protein-bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 1997; 12: 2332-2338.
62. 12. J Biol Chem 2003; 278: 20778-20784.
63. van Guldener C, Kulik W, Berger R et al. Homocysteine and methionine metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56: 1064-1071.